SG11201506335YA - Apelin fusion proteins and uses thereof - Google Patents

Apelin fusion proteins and uses thereof

Info

Publication number
SG11201506335YA
SG11201506335YA SG11201506335YA SG11201506335YA SG11201506335YA SG 11201506335Y A SG11201506335Y A SG 11201506335YA SG 11201506335Y A SG11201506335Y A SG 11201506335YA SG 11201506335Y A SG11201506335Y A SG 11201506335YA SG 11201506335Y A SG11201506335Y A SG 11201506335YA
Authority
SG
Singapore
Prior art keywords
fusion proteins
apelin fusion
apelin
proteins
fusion
Prior art date
Application number
SG11201506335YA
Other languages
English (en)
Inventor
Panayiotis Stevis
Jesper Gromada
Andrew Murphy
Original Assignee
Regeneron Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Regeneron Pharma filed Critical Regeneron Pharma
Publication of SG11201506335YA publication Critical patent/SG11201506335YA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Molecular Biology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Virology (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Communicable Diseases (AREA)
  • Endocrinology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Peptides Or Proteins (AREA)
SG11201506335YA 2013-03-14 2014-03-14 Apelin fusion proteins and uses thereof SG11201506335YA (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361786172P 2013-03-14 2013-03-14
US201361906567P 2013-11-20 2013-11-20
PCT/US2014/028384 WO2014152955A1 (en) 2013-03-14 2014-03-14 Apelin fusion proteins and uses thereof

Publications (1)

Publication Number Publication Date
SG11201506335YA true SG11201506335YA (en) 2015-09-29

Family

ID=50680161

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201506335YA SG11201506335YA (en) 2013-03-14 2014-03-14 Apelin fusion proteins and uses thereof

Country Status (16)

Country Link
US (3) US9353163B2 (ja)
EP (1) EP2970415B1 (ja)
JP (1) JP6525951B2 (ja)
KR (1) KR20150127596A (ja)
CN (1) CN105026423A (ja)
AU (1) AU2014236451B2 (ja)
BR (1) BR112015020587A2 (ja)
CA (1) CA2904731A1 (ja)
EA (1) EA201591700A1 (ja)
ES (1) ES2708957T3 (ja)
HK (1) HK1220466A1 (ja)
IL (1) IL240587A0 (ja)
MX (1) MX365551B (ja)
SG (1) SG11201506335YA (ja)
WO (1) WO2014152955A1 (ja)
ZA (1) ZA201505927B (ja)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2014236451B2 (en) 2013-03-14 2018-08-09 Regeneron Pharmaceuticals, Inc. Apelin fusion proteins and uses thereof
EP3024845A1 (en) 2013-07-25 2016-06-01 Novartis AG Cyclic polypeptides for the treatment of heart failure
CN105705167A (zh) 2013-07-25 2016-06-22 诺华股份有限公司 合成的apelin多肽的生物缀合物
CA2931299C (en) 2013-11-20 2024-03-05 Regeneron Pharmaceuticals, Inc. Aplnr modulators and uses thereof
GB201407532D0 (en) * 2014-04-29 2014-06-11 Univ Ulster Apelin analogues
US10941182B2 (en) 2014-06-10 2021-03-09 Amgen Inc. Apelin polypeptides
US10463716B2 (en) 2014-10-13 2019-11-05 University Of Maryland, Baltimore Methods for treating cardiovascular dysfunction and improving fluid homeostasis with Elabela peptide hormone
WO2016065042A1 (en) * 2014-10-22 2016-04-28 Extend Biosciences, Inc. Therapeutic vitamin d conjugates
WO2016102648A1 (en) * 2014-12-23 2016-06-30 INSERM (Institut National de la Santé et de la Recherche Médicale) Metabolically stable apelin analogs in the treatment of disease mediated by the apelin receptor
CN107106632A (zh) * 2014-12-29 2017-08-29 中央研究院 一种治疗a型流感病毒感染的方法
JP2018507187A (ja) 2015-01-23 2018-03-15 ノバルティス アーゲー 改善された半減期を有する合成アペリン脂肪酸コンジュゲート
AR105616A1 (es) * 2015-05-07 2017-10-25 Lilly Co Eli Proteínas de fusión
CA3057619A1 (en) * 2017-03-22 2018-09-27 Research Corporation Technologies, Inc. Engineered stable ch2 polypeptides
EP3604538A4 (en) * 2017-03-29 2020-12-30 University of Miyazaki LONG-ACTING ADRENOMEDULLINE DERIVATIVE
AU2018266324B2 (en) * 2017-05-06 2024-02-01 Regeneron Pharmaceuticals, Inc. Methods of treating eye disorders with APLNR antagonists and VEGF inhibitors
CN109771634A (zh) * 2017-07-11 2019-05-21 南华大学 含有apelin 12环肽的药物组合物及用途
MX2020002042A (es) * 2017-08-24 2020-08-13 Phanes Therapeutics Inc Anticuerpos anti-apelin y sus usos.
GB201805675D0 (en) * 2018-04-05 2018-05-23 Davenport Anthony Peter Compounds For Use As Apelin Receptor Antagonists
CN110655577A (zh) * 2018-06-13 2020-01-07 鸿运华宁（杭州）生物医药有限公司 APJ抗体及其与Elabela的融合蛋白质，以及其药物组合物和应用
AU2021297998A1 (en) * 2020-06-25 2022-12-15 Gliknik Inc. ACE2-Fc fusion proteins and methods of use
CN112546198B (zh) * 2020-12-17 2022-03-25 温州医科大学慈溪生物医药研究院 一种用于治疗脑中风和急性脑梗的药物组合物
CN113648418B (zh) * 2021-05-08 2022-08-05 南方医科大学 Apelin-APJ抑制剂在制备治疗血睾屏障损伤药物中的应用

Family Cites Families (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
JPS5896026A (ja) 1981-10-30 1983-06-07 Nippon Chemiphar Co Ltd 新規ウロキナ−ゼ誘導体およびその製造法ならびにそれを含有する血栓溶解剤
DE3380726D1 (en) 1982-06-24 1989-11-23 Japan Chem Res Long-acting composition
US4681581A (en) 1983-12-05 1987-07-21 Coates Fredrica V Adjustable size diaper and folding method therefor
US4766106A (en) 1985-06-26 1988-08-23 Cetus Corporation Solubilization of proteins for pharmaceutical compositions using polymer conjugation
US4735210A (en) 1985-07-05 1988-04-05 Immunomedics, Inc. Lymphographic and organ imaging method and kit
US5101827A (en) 1985-07-05 1992-04-07 Immunomedics, Inc. Lymphographic and organ imaging method and kit
US5776093A (en) 1985-07-05 1998-07-07 Immunomedics, Inc. Method for imaging and treating organs and tissues
US5648471A (en) 1987-12-03 1997-07-15 Centocor, Inc. One vial method for labeling antibodies with Technetium-99m
US5703055A (en) 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
DK0486622T3 (da) 1989-08-09 1999-07-19 Rhomed Inc Direkte radiomærkning af antistoffer og andre proteiner med technetium eller rhenium
US6077835A (en) 1994-03-23 2000-06-20 Case Western Reserve University Delivery of compacted nucleic acid to cells
KR970029803A (ko) 1995-11-03 1997-06-26 김광호 반도체 메모리장치의 프리차지 회로
US5972650A (en) 1997-06-26 1999-10-26 Brigham And Women's Hospital Tetracycline repressor regulated mammalian cell transcription and viral replication switch
DE69838986T2 (de) 1997-12-24 2009-01-08 Takeda Pharmaceutical Co. Ltd. Polypeptide, deren herstellung und verwendung
US6475718B2 (en) 1998-09-08 2002-11-05 Schering Aktiengesellschaft Methods and compositions for modulating the interaction between the APJ receptor and the HIV virus
US6281005B1 (en) 1999-05-14 2001-08-28 Copernicus Therapeutics, Inc. Automated nucleic acid compaction device
EP1228214A2 (en) * 1999-11-12 2002-08-07 MERCK PATENT GmbH Erythropoietin forms with improved properties
AU2001296023A1 (en) 2000-10-30 2002-05-15 Takeda Chemical Industries Ltd. Process for producing peptide
US20090137416A1 (en) 2001-01-16 2009-05-28 Regeneron Pharmaceuticals, Inc. Isolating Cells Expressing Secreted Proteins
AU2002245272B2 (en) 2001-01-16 2006-06-29 Regeneron Pharmaceuticals, Inc. Isolating cells expressing secreted proteins
DE10138569A1 (de) 2001-08-06 2003-04-30 Bayer Ag Regulation des APJ-Rezeptors
US8673589B2 (en) 2002-05-29 2014-03-18 Regeneron Pharmaceuticals, Inc. Inducible eukaryotic expression system
DE602004027798D1 (de) 2003-03-12 2010-08-05 Univ Arizona State Verfahren zur regulierung von angiogenese mit apelin-zusammensetzungen
US7450586B2 (en) * 2003-07-22 2008-11-11 Motorola, Inc. Network header compression arrangement
JP2008504012A (ja) * 2004-01-28 2008-02-14 シントニックス・ファーマシューティカルズ・インコーポレーテッド 不妊治療のためのへテロ二量体卵胞刺激ホルモン−Ｆｃ（ＦＳＨ−Ｆｃ）融合タンパク質
WO2005106493A1 (en) 2004-04-30 2005-11-10 Bayer Healthcare Ag Diagnostics and therapeutics for diseases associated with g protein-coupled apelin receptor (apj)
WO2006023893A2 (en) 2004-08-23 2006-03-02 Arizona Board Of Regents On Behalf Of The University Of Arizona Methods for modulating angiogenesis and apoptosis with apelin compositions
US20060159676A1 (en) 2005-01-14 2006-07-20 Krieg Paul A Methods for modulating angiogenesis, lymphangiogenesis, and apoptosis with apelin compositions
US8673848B2 (en) * 2012-01-27 2014-03-18 Novartis Ag Synthetic apelin mimetics for the treatment of heart failure
EP1967210A4 (en) 2005-12-20 2009-11-11 Takeda Pharmaceutical NEW APPLICATION OF APÉLINE
US7867491B2 (en) * 2007-05-30 2011-01-11 Genexine Co., Ltd. Immunoglobulin fusion proteins
PL2150617T3 (pl) 2007-06-04 2015-04-30 Regeneron Pharma Wzmocniona ekspresja i regiony stabilności
WO2010053545A2 (en) 2008-11-04 2010-05-14 Anchor Therapeutics, Inc. Apj receptor compounds
CA2753287A1 (en) * 2009-02-24 2010-09-02 Glaxo Group Limited Antigen-binding constructs
US8946382B2 (en) 2009-02-27 2015-02-03 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Apelin peptides and methods of use
US9174428B2 (en) * 2009-08-10 2015-11-03 Corning Incorporated Roll mechanics for enabling printed electronics
SG10201912571XA (en) 2009-11-02 2020-02-27 Univ Washington Therapeutic nuclease compositions and methods
TW201138808A (en) * 2010-05-03 2011-11-16 Bristol Myers Squibb Co Serum albumin binding molecules
WO2012016227A2 (en) * 2010-07-29 2012-02-02 Xencor, Inc. Antibodies with modified isoelectric points
US8881594B2 (en) * 2011-03-06 2014-11-11 Alexander Henry Slocum Tapered spiral bellows pressure sensor
US20140142049A1 (en) * 2011-03-11 2014-05-22 Zhiqiang Jia Pegylated apelin and uses thereof
JPWO2012133825A1 (ja) 2011-03-31 2014-07-28 株式会社 資生堂 ホットフラッシュの抑制剤
WO2013012855A1 (en) 2011-07-18 2013-01-24 Amgen Inc. Apelin antigen-binding proteins and uses thereof
CN106931333B (zh) * 2011-11-23 2020-11-27 夸克星有限责任公司 发光装置
CN102516393B (zh) 2011-11-30 2017-03-15 北京康明百奥新药研发有限公司 胰岛素模拟肽融合蛋白和突变体及其应用
CN102675470B (zh) * 2012-04-01 2015-06-17 江苏省弗泰生物科技有限公司 SCF-Fc融合蛋白
EP3907237A1 (en) 2012-12-20 2021-11-10 Amgen Inc. Apj receptor agonists and uses thereof
AU2014236451B2 (en) 2013-03-14 2018-08-09 Regeneron Pharmaceuticals, Inc. Apelin fusion proteins and uses thereof
CA2931299C (en) 2013-11-20 2024-03-05 Regeneron Pharmaceuticals, Inc. Aplnr modulators and uses thereof

Also Published As

Publication number Publication date
EA201591700A1 (ru) 2015-12-30
EP2970415A1 (en) 2016-01-20
US20180030099A1 (en) 2018-02-01
AU2014236451A1 (en) 2015-10-15
US20140275489A1 (en) 2014-09-18
WO2014152955A1 (en) 2014-09-25
CA2904731A1 (en) 2014-09-25
HK1220466A1 (zh) 2017-05-05
US9751921B2 (en) 2017-09-05
KR20150127596A (ko) 2015-11-17
AU2014236451B2 (en) 2018-08-09
MX2015011350A (es) 2016-01-15
US20160237130A1 (en) 2016-08-18
US9353163B2 (en) 2016-05-31
MX365551B (es) 2019-06-07
ZA201505927B (en) 2017-03-29
EP2970415B1 (en) 2018-12-19
ES2708957T3 (es) 2019-04-12
JP2016513733A (ja) 2016-05-16
JP6525951B2 (ja) 2019-06-05
BR112015020587A2 (pt) 2017-10-10
IL240587A0 (en) 2015-09-24
CN105026423A (zh) 2015-11-04

Similar Documents

Publication Publication Date Title
IL276106A (en) Garp-binding proteins and their uses
HK1220466A1 (zh) 愛帕琳融合蛋白和其用途
IL261743B (en) and their uses 33–il antibodies against
IL240034A0 (en) Chimeric proteins based on l1–pd and –pd–l2 and their uses
IL261547B (en) Antibodies against pesidine and their uses
IL245040A0 (en) Antibodies against pdgfr-beta and their uses
IL243974B (en) Antibodies against –prlr and uses
ZA201508896B (en) Anti-c10orf54 antibodies and uses thereof
EP2968551A4 (en) FUSION PROTEINS AND METHOD THEREFOR
SG11201509116VA (en) Anti-tweakr antibodies and uses thereof
GB201316592D0 (en) Fusion protein
HK1220903A1 (zh) 軟骨結合型融合蛋白
HUE054423T2 (hu) Fúziós polipeptidek és vakcinák
EP2930189A4 (en) CHEMOKINE-CYTOKINE FUSION PROTEIN AND USE THEREOF
EP3029071A4 (en) Saxatilin-fc fusion protein and use thereof
AU2013901331A0 (en) Fusion Proteins and Use Thereof